ADMA Biologics Inc
NASDAQ:ADMA
Net Margin
ADMA Biologics Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | US |
Market Cap | 2.1B USD |
Net Margin |
-1%
|
Country | US |
Market Cap | 287.8B USD |
Net Margin |
9%
|
Country | US |
Market Cap | 169.8B USD |
Net Margin |
13%
|
Country | US |
Market Cap | 111.9B USD |
Net Margin |
37%
|
Country | US |
Market Cap | 107.4B USD |
Net Margin |
29%
|
Country | AU |
Market Cap | 136.7B AUD |
Net Margin |
17%
|
Country | US |
Market Cap | 84B USD |
Net Margin |
2%
|
Country | US |
Market Cap | 48B USD |
Net Margin |
-116%
|
Country | US |
Market Cap | 43.1B USD |
Net Margin |
-33%
|
Country | US |
Market Cap | 33.8B USD |
Net Margin |
12%
|
Country | KR |
Market Cap | 39.6T KRW |
Net Margin |
25%
|
Profitability Report
View the profitability report to see the full profitability analysis for ADMA Biologics Inc.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on ADMA Biologics Inc's most recent financial statements, the company has Net Margin of -1.3%.